Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid

This study was designed to be a retrospective, multicentre, observational study to evaluate the efficacy and safety of dupilumab in the treatment of bullous pemphigoid and to find predictors of efficacy.

Inclusion Criteria:Adult bullous pemphigoid patients treated with dupilumab between January 1, 2021, and July 31, 2022, at six leading dermatology departments in the Chinese Collaborative Network for Autoimmune Bullous Diseases.The diagnosis of BP requires clinical manifestations and immunological or pathological evidences.Dupilumab treatment should continue for at least 4 weeks and possibly longer.Exclusion Criteria:Drug-induced BP, γ-1 pemphigoidPatients with less than 4 weeks of follow-upPatients were given any other biologicals within 6 months before the first dupilumab administration